Methods and compositions for treatment of bone defects with placental cell populations
First Claim
1. A method for treating a bone defect in a subject, wherein said bone defect is an osteolytic lesion associated with multiple myeloma, bone cancer, or metastatic cancer characterized by bone metastases, comprising administering to a subject in need thereof an implantable or injectable composition comprising a population of placental stem cells, wherein said population is predominantly CD34−
- , CD10+, CD105+, and CD200+;
wherein said stem cells express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs);
and wherein said genes comprise ELOVL2, ST3GAL6, ST6GALNAC5, or SLC12A8;
thereby treating the bone defect in the subject.
3 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
-
Citations
20 Claims
-
1. A method for treating a bone defect in a subject, wherein said bone defect is an osteolytic lesion associated with multiple myeloma, bone cancer, or metastatic cancer characterized by bone metastases, comprising administering to a subject in need thereof an implantable or injectable composition comprising a population of placental stem cells, wherein said population is predominantly CD34−
- , CD10+, CD105+, and CD200+;
wherein said stem cells express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs); and wherein said genes comprise ELOVL2, ST3GAL6, ST6GALNAC5, or SLC12A8; thereby treating the bone defect in the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- , CD10+, CD105+, and CD200+;
Specification